FDA
-
-
-
-
-
-
-
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
-
-
-
-
-
-
-
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
-
-
-
-
-
-
-
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
-
-
-
-
-
-
-
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
-
-
-
-
-
-
-
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Ardelyx Announces Departure of Board Member
-
-
-
-
-
-
-
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

